Superiority Standard? Groups Bristle At CMS’ Transcatheter Valve Trial Proposal
This article was originally published in The Gray Sheet
Executive Summary
Some worry that a provision in CMS’ proposed national coverage decision for transcatheter aortic valve replacement devices, which restricts coverage for off-label indications to trials designed to show superiority, signals the agency’s intent to play a more active role in dictating trial designs.